Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Myelofibrosis Research Highlights from the 2024 ASH Conference

December 16, 2024

Read about the myelofibrosis research highlights from the 2024 ASH conference.

The Best of ASH 2024

December 10, 2024

Discover the board's selection of best abstracts at the 66th annual ASH conference.

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

December 10, 2024

Read research highlights from the ASH 2024 conference how certain lifestyle choices affect blood cancers.

ASH 2024 Begins! A Symposium on MF Care: And Why It Matters to You

December 06, 2024

Top myelofibrosis specialists gathered to discuss mastering the art of MF care. Case studies shaped the discussion. Learn more!

What is the ASH Conference?

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in MF research.

Testing a New Combination Therapy for Myelofibrosis Treatment

August 12, 2024

Navitoclax with Ruxolitinib in Phase III trial shows promise for myelofibrosis, significantly reducing spleen size and improving patient symptoms.

ASCO 2024: The MANIFEST-2 Study for Myelofibrosis

June 12, 2024

Discover the latest in myelofibrosis: Phase 3 study shows promising results for Pelabresib + Ruxolitinib, reducing spleen size and improving symptoms.

What is the ASCO Conference?

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

ASH 2023: Navitoclax And Ruxolitinib Trials to Treat Myelofibrosis

February 26, 2024

ASH 2023 results reveal that a JAK inhibitor combined with navitoclax, a BCL-2 inhibitor showed success in myelofibrosis.

ASH 2023: Cardiovascular Complications and Myelofibrosis

January 08, 2024

A study at the 2023 ASH conference compared heart disease complications among myelofibrosis patients who received ruxolitinib vs those who did not.

Conferences

Recent Articles